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Apoptosis-related mechanisms are important in the pathophysiology of hypoxic–ischemic injury in the
neonatal brain. Caspases are the major executioners of apoptosis, but there are a number of upstream
players that influence the cell death pathways. The Bcl-2 family proteins are important modulators of
mitochondrial permeability, working either to promote or prevent apoptosis. In this study we focused
on the anti-apoptotic Bcl-2 protein after neonatal cerebral hypoxia–ischemia (HI) in 8-day-old rats.
Bcl-2 translocated to nuclei and accumulated there over the first 24 h of reperfusion after HI, as judged
by immunohistochemistry and immuno-electron microscopy. We also found that the total level of Bcl-2
decreased after HI in vivo and after ionophore challenge in cultured human neuroblastoma (IMR-32) cells
in vitro. Furthermore, the Bcl-2 reduction was calpain-dependent, because it could be prevented by the
calpain inhibitor CX295 both in vivo and in vitro, suggesting cross-talk between excitotoxic and apoptotic
mechanisms.
 2009 Elsevier Inc. All rights reserved.1. Introduction
Hypoxic–ischemic (HI) brain injury resulting from perinatal as-
phyxia remains a clinical problem, in spite of increased knowledge
of the pathophysiology (Blomgren et al., 2003; Johnston et al.,
2002). Hypothermia has been the only effective means for neuro-
protection (Shankaran et al., 2005), but recently erythropoietin
treatment has also emerged as a promising strategy (Zhu et al.,
2009). However, additional strategies and treatments are needed.
It is today acknowledged that apoptosis-related mechanisms con-
tribute to the tissue damage that occurs after HI injury, especiallyll rights reserved.
ng factor 1; Bax, Bcl-2-asso-
ytochrome c oxidase subunit
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e associated protein 2.
n Repair and Rehabilitation,
othenburg, P.O. Box 432, SE-
mgren).when it affects the developing brain (Hu et al., 2000; Zhu et al.,
2005), but the molecular mechanisms need to be investigated
further. Apoptotic cell death includes caspase-dependent and -
independent pathways (Blomgren et al., 2007, 2001; Cheng et al.,
1998; Zhu et al., 2003). Several intracellular apoptosis-related
pathways have been identified in which mitochondria are pivotal
regulators in the process of cell death and survival, both through
their roles in energy metabolism and calcium homeostasis, but also
because of their capacity to release pro-apoptotic proteins
(Blomgren et al., 2003; Zhu et al., 2003). The different pathways
for induction of apoptosis converge upon the activation of cas-
pase-3 or the translocation of apoptosis-inducing factor (Blomgren
et al., 2007; Zhu et al., 2007).
The Bcl-2 family proteins are involved in the control of apopto-
sis both upstream of and at the level of mitochondria, representing
a critical proximal intracellular checkpoint. The Bcl-2 family con-
sists of at least 20 pro- or anti-apoptotic members. Induction of cell
death signaling in neurons is prevented by death suppressors (e.g.
Bcl-2), and promoted by for example Bax or Bid (Galluzzi et al.,
2009). Over-expression of the anti-apoptotic Bcl-2, deletion of
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drial pore formation increases the resistance to ischemic insults,
indicating that mitochondrial pathways are involved in neuronal
cell death (Gibson et al., 2001; Hetz et al., 2005; Martinou et al.,
1994). HI induces Bax translocation from cytosol to mitochondria
leading to cytochrome c release from the mitochondrial intermem-
brane space, which in turn activates caspase-9 and subsequently
caspase-3 (Northington et al., 2001). The anti-apoptotic protein
Bcl-2 can interfere with the Bax translocation to mitochondria
and thereby block the release of apoptotic proteins (Ferrer and Pla-
nas, 2003), and Bcl-2 can probably prevent opening of the mito-
chondrial membrane permeability transition pore (Zoratti and
Szabo, 1995). The balance of the pro- vs anti-apoptotic Bcl-2 family
proteins seems critical for the development of neonatal HI brain in-
jury (Gibson et al., 2001; Hallin et al., 2006).
Calpains are calcium-dependent cysteine proteases usually
implicated in necrosis, but they have also been shown to be in-
volved in cell death after HI, either in concert with caspases or
independently (Blomgren et al., 2001; Leist and Jäättelä, 2001;
Nakagawa and Yuan, 2000). Lately, calpains have also been impli-
cated in caspase-independent apoptosis, in the release of AIF from
mitochondria (Norberg et al., 2008), although this concept has
been challenged (Joshi et al., 2009; Wang et al., 2009). Calpains
can function upstream of caspases and procaspase-3 has been
demonstrated to be a calpain substrate in vitro (McGinnis et al.,
1999) and in vivo (Blomgren et al., 2001). Some of the Bcl-2 family
proteins are known to be cleaved by calpains (Wood et al., 1998) or
caspases (Cheng et al., 1997; Choi et al., 2001) influencing their
function. Understanding the interaction between calpains and
caspases will help unravel the molecular mechanisms that activate
the death executioners and will provide new insights for the design
of strategies to ameliorate the effects of HI brain injury. The aim of
this study was to investigate the cellular distribution of Bcl-2 after
HI in the neonatal rat brain and explore the possible interaction
between calpains and Bcl-2.2. Materials and methods
2.1. Induction of unilateral hypoxic–ischemic brain injury
Wistar rats of both genders were operated according to the
Rice-Vannucci model (Rice et al., 1981; Zhu et al., 2003) on postna-
tal day 8 (P8). In brief, the left common carotid artery was cut be-
tween double ligatures of prolene sutures (6–0) under enflurane
anesthesia, 3–4% for induction followed by 1–2% for maintenance.
The wound was sutured and infiltrated with lidocaine for analge-
sia. The pups were left with their dam to recover for about 1 h
and then placed in a humidified chamber, pre-warmed to 36 C.
The chamber was perfused with air for 10 min followed by a period
of 55 min in 7.8% oxygen in nitrogen followed by another 10 min
with air. The air and the gas mixture were humidified and pre-
heated (36 C) before entering the chamber. Control animals were
subjected neither to ligation nor hypoxia. All animal experimenta-
tion was approved by the Ethical Committee of Gothenburg (182-
99 and 288-02).2.2. Calpain Inhibition in vivo
Pups were treated with the calpain inhibitor CX295 (Z-Leu-ami-
nobutyric acid-CONH(CH2) 3-morpholine; Cortex Pharmaceuticals,
Irvine, CA) or vehicle (n = 8/group). The first dose, 200 ll of 5 mM
CX295 in 100 mM NaCl (equivalent to 80 lmol/kg or 40 mg/kg
body weight), was administered subcutaneously immediately after
HI. Subsequently, animals were injected with 100 ll of the CX295
solution (equivalent to 40 lmol/kg or 20 mg/kg body weight)every 3 h for 24 h. Control animals were injected with 100 mM
NaCl.
2.3. Immunoblotting
Animals were sacrificed by decapitation 2, 6 or 24 h after HI.
Control animals were sacrificed on postnatal day 8. The brains
were rapidly dissected out on a bed of ice. The parietal cortex
and diencephalon were dissected out from each hemisphere and
ice-cold isolation buffer was added [15 mM Tris–HCl, pH 7.6,
320 mM sucrose, 1 mM dithiothreitol (DTT), 3 mM EDTA-K, 0.5%
protease inhibitor cocktail (Sigma) and 2.5 lM cyclosporine A (Sig-
ma)]. Homogenization was performed gently by hand (to preserve
mitochondrial integrity) in a 2-mL glass/glass homogenizer (Merck
Eurolab, Göteborg, Sweden) using, sequentially, two different pes-
tles with a total clearance of 0.12 and 0.05 mm, respectively. The
homogenates were centrifuged at 800g at 4 C for 10 min. The
supernatants were further centrifuged at 9200g for 15 min at
4 C, producing mitochondrial and synaptosomal fractions in the
pellets (P2) and crude cytosolic fractions in the supernatants
(S2). The P2 (mitochondrial) fractions were washed and recentri-
fuged. The S2 fraction was centrifuged for 40 min at 100,000g at
+4 C yielding a cytosolic fraction (S3) in the supernatant. A set
of control animals (aged 0, 3, 7, 14, 21, 42 and 60 days) were sac-
rificed and their brains collected as described above. All fractions
were stored at 80 C. The protein concentrations were deter-
mined according to Whitaker and Granum (Whitaker and Granum,
1980), adapted for microplates, using a Spectramax Plus plate
reader (Molecular Devices, Sunnyvale, CA, USA). When brain samples
were pooled, equal amounts of total protein from 6 animals per
group were mixed.
In the case of IMR-32 cells all experiments were repeated in
triplicate. For sample preparation, please see below. SDS–PAGE
was performed using 4–12% Tris–glycine gels (Novex, San Diego,
CA) and proteins were transferred to enhanced nitrocellulose
membranes (Schleicher & Schuell, Dassel, Germany). For detection
of Bcl-2 and Bax, polyclonal rabbit antibodies (sc-492 and sc-493,
respectively, Santa Cruz Biotechnology) were used, diluted 1:1000.
Active m-calpain was detected by immunoblotting using a rabbit
polyclonal antibody diluted 1:1000 (a kind gift from Dr. Mitsushi
Inomata, Tokyo Metropolitan Institute of Gerontology, Tokyo, Ja-
pan) (Manya et al., 2002). Anti-caspase-12 (Oncogene, PC558)
was diluted 1:2000. Anti-a-fodrin (Biomol, Plymouth Meeting,
PA, USA) was diluted 1:500. Equal loading of protein was con-
firmed using rabbit anti-actin (1:200, A2066, Sigma, Stockholm,
Sweden) or mouse anti-Cox IV (1:500, A21344, Molecular Probes,
Eugene, USA). Peroxidase-labeled secondary goat-anti-rabbit IgG
(1:2000), horse anti-goat (1:2000) horse anti-mouse (1:4000) anti-
bodies were from Vector Laboratories (Burlingame, CA, USA). Immu-
noreactive bands were visualized using Super Signal West Dura
(Pierce, Rockford, IL, USA) chemiluminescent substrate and a LAS-
3000 cooled CCD-camera (Fujifilm, Tokyo, Japan).
2.4. Immunohistochemistry
At 2, 6, 14 or 24 h after HI or on postnatal day 8 for controls, the
animals were deeply anesthetized with an intraperitoneal injection
of phenobarbital and sacrificed by perfusion fixation with 4% neu-
tral buffered formaldehyde (Histofix, Histolab Products AB Sweden).
Brains were dissected out and immersed in the same fixative over-
night, dehydrated by passing through a graded series of ethanol,
cleared in xylene, embedded in paraffin and cut frontally to 5 lm
sections. Sections were deparaffinized, rehydrated and stained for
Bcl-2 (polyclonal rabbit-anti-Bcl-2; Santa Cruz Biotechnology: sc-
783). Antigen retrieval was performed by heating the sections in
10 mM citrate buffer, pH 6.0 for 10 min. Non-specific protein bind-
Fig. 1. Postnatal expression of Bcl-2 and Bax in rat brain. Immunoblots of pooled
homogenate samples from postnatal day (P) 0, 3, 7, 14, 21, 42 and 60 rats
demonstrating downregulation of both Bcl-2 and Bax during normal brain
development. Actin immunoblots demonstrate equal loading.
Fig. 2. Bcl-2 immunoblots of pooled cortical homogenates, mitochondrial fractions
and cytosolic fractions after HI. (A) Bcl-2 expression in pooled brain homogenates
(n = 6/group) from 8-day-old normal control rats (Cont) or 2, 6 and 24 h after HI,
demonstrating degradation in the ipsilateral (IL) hemisphere at early recovery.
During late recovery, 24 h post-HI, there was no longer any obvious reduction
compared with the contralateral (CL) hemisphere. (B) Bcl-2 was reduced in the
mitochondrial (P2) fractions from ipsilateral hemispheres as early as 2 h post-HI,
and was even more reduced after 24 h. (C) Bcl-2 increased dramatically in the
soluble, cytosolic (S3) fraction of both hemispheres, most pronounced at 2 h post-
HI. The nature of the heavier (approx. 28 kDa) band is not clear. The actin and COX
IV immunoblots demonstrate equal loading. (D) The bar graph shows the relative
amount of Bcl-2 remaining in the cytosolic fraction of the ipsilateral compared to
the contralateral hemisphere after densitometric quantification of Bcl-2 bands from
the respective hemispheres.
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goat anti-rabbit secondary antibodies were from Vector (Burlin-
game, CA, USA). Endogenous peroxidase activity was blocked by
0.6% hydrogen peroxide in methanol and the signal was enhanced
using biotinylated avidin–biotin complex (Vectastain ABC Elite,
Vector) with 0.5 mg/mL 3,30-diaminobenzidine (DAB) enhanced
with 15 mg/mL ammonium nickel sulfate, 2 mg/mL b-D-glucose,
0.4 mg/mL ammonium chloride and 0.01 mg/mL beta-glucose oxi-
dase (Sigma). Negative controls were performed by excluding the
primary antibody as well as by preabsorption of the primary
antibodies with the antigen used to raise the antibody. The number
of Bcl-2 immunopositive cells was counted in a blinded manner in
the cortex and dentate gyrus of ipsilateral hemispheres. In the
cortex, cells were counted in four adjacent visual fields, each
with an area of 180  103 lm2, in the injured, MAP-2-negative
(or corresponding) area. The whole dentate gyrus was similarly
investigated.
2.5. Fluorescence microscopy
After dehydration and antigen retrieval as above, non-specific
protein binding was blocked using 4% normal donkey serum in
PBS. Incubation with anti-Bcl-2 (diluted 1:150) was performed
over night at 4 C. A secondary antibody (Alexa Fluor 555, don-
key-anti-rabbit IgG; diluted 1:500) (Jackson ImmunoResearch, PA,
USA) was applied for 60 min at 22 C. A second blocking step with
0.1 M Tris–HCl, pH 7.5 containing 3% BSA for 30 min was followed
by washing with PBS and incubation with TUNEL reaction mixture
for 60 min at 37 C. After washing, the sections were mounted
using Vectashield mounting medium with DAPI (DAKO Corporation,
Carpinteria, CA, USA).
2.6. Electron microscopy
Pups were deeply anesthetized with an intraperitoneal injection
of phenobarbital and sacrificed by perfusion fixation with a freshly
made solution of 4% paraformaldehyde in 0.1 M phosphate buffer
(pH 7.4) at 2 or 24 h after HI. The brains were dissected out,
post-fixed in the same solution for 2 days at +4 C and stored in
0.1 M phosphate buffer at +4 C up to 24 h until sectioning. Control
animals were sacrificed on postnatal day 8. The hemispheres were
separated, the left hemisphere was mounted and cut frontally to
50 lm sections on an Oxford vibratome. All subsequent incubations
were performed with free floating 50 lm thick sections in a
12-well cell culture plate (Costar) on a rocking plate at room tem-
perature. After rinsing in PBS, sections were incubated with 0.05%
glycine in PBS, rinsed again with PBS, blocked and permeabilized
over night at +4 C in a solution of 1% PVP 40 and 0.5% Tween 20
in PBS (PBS-PT). Sections were washed with PBS-T (0.01% Tween
20) and incubated with polyclonal rabbit-anti-Bcl-2 (1:100 in 1%
PVP 40, PBS-T, Santa Cruz Biotechnology: sc-783) at +4 C over night.
Negative control sections were incubated in PBS-PT only. After
rinsing in PBS-T, sections were incubated with biotinylated goat
anti-rabbit secondary antibody (1:500 in PBS-PT) for 4 h at 22 C.
They were washed in PBS-T and incubated with avidin–biotin com-
plex (Vectastain ABC Elite kit, DAKO) for 60 min. A final rinse in PBS
was performed before the sections were washed in 0.1 M sodium
acetate buffer, pH 6.0 and the immunoreactivity developed as
above. Finally, the sections were washed with PBS and stored in
PBS at +4 C over night. Sections were rinsed in 0.1 M phosphate
buffer (pH 7.4) for 20 min, post-fixed with 1% osmium tetroxide
in 0.1 M phosphate buffer for 30 min and rinsed again in phosphate
buffer for 15 min. Dehydration was performed using a graded ser-
ies of acetone: 15 min each in 50%, 70%, 80% and 90% acetone, then
three times 15 min in 100% acetone. Sections were infiltrated with
30% Vestopal W plastic (Promochem, Boras, Sweden) (diluted in 100%acetone) for 60 min followed by over night (16 h) infiltration with
60% Vestopal W at +4 C, 7 h of infiltration with 100% Vestopal W at
22 C after which they were put in +4 C over night. The sections
were flat-embedded in Vestopal W, and the plastic was allowed
to polymerize, at 45 C for 2 h, then 60 C for 2 days. Samples were
selected for ultramicrotomy from the immunostained and embed-
ded vibratome sections. After cutting from the vibratome section,
specimens were mounted on premoulded Vestopal W holders using
‘‘Loctite Super Attak” glue (Loctite Corporation, Loctite Sweden AB).
Thin sections (1000 or 1500 Å) were cut using an LKB III ultrotome
and placed on formvar-coated one-hole copper grids. The 1000 Å
sections were contrasted with uranyl acetate and lead citrate for
evaluation of cellular morphology, while the 1500 Å sections were
used for evaluation of the immunohistochemical staining. The
samples were evaluated using a Philips 400 transmission electron
microscope.
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Human neuroblastoma cells (IMR-32) were cultured and ampli-
fied in RPMI-1640 medium (BE12-167, Bio-Whittaker, Verviers,
Belgium). On day 5, when cells had reached 80–90% confluence,
they were treated with 0, 50 or 100 lM calpain inhibitor, cx-295
(Cortex Pharmaceuticals, Irvine, CA) for 60 min, then stimulated
with 0, 25 or 50 lM thapsigargin for 4 h. Adherent cells were
resuspended by mechanical scraping and then suspended in fresh
medium. The suspension was centrifuged at 1500 rpm for
10 min, the supernatant was discarded and the pellet mixed with
an equal volume of lysis buffer (20 mM Tris, 5 mM EDTA, 1 mM
EGTA, 10 mM b-mercaptoethanol, 10 lM APMSF, 150 mM NaCl,
8 mM CHAPS, 0.025% protease inhibitor cocktail and 0.25 M su-
crose). Samples were mixed with equal volumes of concentrated
(3) buffer, heated at 96 C for 5 min and then stored at 20 C.
SDS–PAGE electrophoresis and immunoblotting were performed
as above. Three independent sets of experiments were performed
to validate the findings. Alternatively, subcellular fractionation
was performed by sequential centrifugation steps: the lysate was
centrifuged for 10 min at 800g at +4 C, yielding P1 and S1 frac-
tions. The S1 fraction was centrifuged for 15 min at 9200g at
+4 C resulting in P2 and S2 fractions. Finally, the S2 fraction was
centrifuged for 2 h at 54,000g at +4 C yielding P3 and S3 fractions.Fig. 3. Bcl-2 immunohistochemistry staining after HI. Representative pictures of Bcl
magnification demonstrates cytoplasmic staining in neurons (long arrow) and absence of
areas of injury, nuclear Bcl-2 staining in neurons (long arrow) and staining in the endoth
are indicated in (A) and (B), respectively, at lower magnification by rectangles designated
arrow), was counted in the cortex (E) and in the dentate gyrus (F). The numbers increase
control.Pellets were resuspended in lysis buffer and protein concentrations
determined as above. Samples were mixed with equal volumes of
concentrated (3) buffer, heated at 96 C for 5 min and then stored
at 20 C.2.8. Statistics
All data are expressed as mean ± s.e.m. Cell counting was ana-
lyzed using ANOVA and Fisher’s post hoc test. The percentage of
Bcl-2 reduction after HI in vehicle- or CX295-treated rats was ana-
lyzed using Mann–Whitney U test. Statistical significance was as-
sumed at p < 0.05.3. Results
3.1. Developmental changes
Both Bcl-2 and Bax were highly expressed in the rat cortex dur-
ing postnatal brain development and the expression decreased as
brain growth leveled out (Fig. 1). Bcl-2 dropped 70% between the
day of birth and postnatal day 7, whereas Bax expression decreased
more slowly, displaying a 70% reduction between the day of birth
and postnatal day 21 (Fig. 1).-2 immunostaining in a normal control brain (A) and 24 h after HI (B). Higher
immunoreactivity in endothelium (short arrow) in the normal control cortex (C). In
elium (short arrow) were observed 24 h after HI (D). The areas shown in (C) and (D)
‘‘c” and ‘‘d”. The number of cells with nuclear Bcl-2 immunoreactivity, as in (D) (long
d several-fold during reperfusion. *p < 0.05; **p < 0.01; ***p < 0.001 compared with
Fig. 4. Double labeling of Bcl-2 and TUNEL in injured cortex at 2 h and 24 h after HI.
Representative immunoreactivity for TUNEL (green), Bcl-2 (red), Hoechst 33342
(blue) and overlays in the ipsilateral cortex 2 h (A) and 24 h (B) after HI. Nuclear Bcl-
2 staining was largely colocalized with the DNA damage marker TUNEL in cells
displaying a pyknotic nuclear morphology at early recovery after HI (A) and, even
more pronounced at later recovery, in penumbral areas 24 h after HI (B). Scale
bar = 10 lm.
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The 26 kDa Bcl-2 band decreased 20% in homogenates from the
ipsilateral hemisphere 6 h after HI, but there was no obvious
change 24 h after HI in the ipsilateral compared to the contralat-
eral hemispheres (Fig. 2A). In mitochondrial (P2) fractions, Bcl-2
decreased after HI in ipsilateral hemispheres, more pronounced
at 6 and 24 h of recovery than 2 h after HI. This indicates a pro-
gressive and sustained loss of Bcl-2 in mitochondria even after
the overall levels have normalized (Fig. 2B). In cytosolic (S3) frac-
tions, double bands of Bcl-2 were detected, the heavier band being
the more prominent, both in controls and after HI (Fig. 2C). In-
creased levels of both the heavier band and the lower band were
found in cytosolic fractions from both hemispheres 2 and 6 h after
HI, most pronounced at 2 h in the contralateral hemisphere, indi-
cating release of Bcl-2 into the soluble fraction (Fig. 2C). The lower
band was most pronounced after 2 h reperfusion (Fig. 2C). Densi-
tometry analysis of the lower band showed a decrease in the ipsi-
lateral hemisphere with prolonged reperfusion (Fig. 2D). In tissue
sections, Bcl-2 was found to be widely distributed in all brain re-
gions of normal neonatal rats, displaying the strongest staining in
neurons, whereas endothelial cells were left clearly unstained
(Fig. 3A and C). Following HI, the overall Bcl-2 staining decreased
in the damaged areas (Fig. 3B and D), as confirmed by immuno-
blotting (Fig. 2A). The few, strongly immunopositive cells remain-
ing in the injured areas displayed a predominantly nuclear
staining, particularly 24 h post-HI, including both neurons and
endothelial cells (Fig. 3B and D). The number of nuclei exhibiting
Bcl-2 immunoreactivity increased significantly in all investigated
brain areas after the HI insult (Fig. 3E and F). Immunofluorescent
triple labeling demonstrated that Bcl-2 immunoreactivity could be
detected in the nucleus mainly in cells displaying DNA damage, as
judged by TUNEL staining (Fig. 4). TUNEL-labeled nuclei in the
penumbral region displayed a high degree of colocalization with
Bcl-2 immunoreactivity both at 2 h (Fig. 4A) and 24 h (Fig. 4B)
after HI. The number of double-labeled nuclei increased during
reperfusion, as shown also for the number of nuclei with Bcl-2
staining (Fig. 3E and F). Immuno-electron microscopy confirmed
the results obtained by immunoblotting and immunohistochemis-
try. Bcl-2 immunoreactivity in the control tissue was distributed
in a relatively weak and diffuse pattern throughout the cytoplasm,
without any distinctly labeled organelles (Fig. 5A and B). Immuno-
reactivity was neither found in association with neuronal nuclei
(Fig. 5A), nor in endothelial cells (Fig. 5B) in the non-ischemic
brain. After 2 h of reperfusion, distinct immunoreactivity also ap-
peared in association with nuclei and membrane-bound organ-
elles (Fig. 5C), some of which appeared to be mitochondria.
Furthermore, labeling now appeared in endothelial cells
(Fig. 5D). After 24 h of reperfusion, even stronger immunoreactiv-
ity was present closely associated with the nuclear membrane,
and some intranuclear immunoreactivity was also observed
(Fig. 5E). A number of more strongly labeled, membrane-bound
organelles appeared 24 h post-HI (Fig. 5E), occasionally at struc-
tures appearing to be nuclear pores (Fig. 5E and G). Increased
cytoplasmic staining was found in endothelial cells 24 h post-HI
(Fig. 5F). No immunoreactivity was found in the negative control
sections (Fig. 5H).
3.3. Calpain-dependent reduction of Bcl-2 in vivo and in vitro
The amount of soluble Bcl-2, the lower band, in the cytosolic
fraction was reduced in the ipsilateral hemisphere 24 h after HI,
as indicated by immunoblotting (Fig. 6). Treatment with the cal-
pain inhibitor CX295 prevented this reduction of Bcl-2 in the
ipsilateral hemisphere. To confirm this calpain-dependent down-
regulation of Bcl-2 in vivo, we challenged IMR-32 cells with theionophore thapsigargin and analyzed the levels of Bcl-2 protein
in the lysates. The active form of m-calpain increased in a dose-
Fig. 5. Bcl-2 immuno-electron microscopy in the cortex. (A) Diffuse cytoplasmic staining is present in normal control neurons, not clearly associated with any organelles. The
thin arrow points to a non-labeled membranous organelle. No immunoreactivity is seen at the nuclear membrane (bold arrow). (B) The arrowhead shows endothelium
without labeling. Short arrows show unlabeled organelles. Long arrows show diffuse cytoplasmic labeling in non-endothelial cells. (C) A neuronal mitochondrion (long arrow)
and other membrane-bound organelles (short arrows) exhibit membrane-associated labeling 2 h after HI. The bold arrow shows a site of immunoreactivity close to the
nucleus. (D) Staining appearing in endothelial cytoplasm (arrowheads) 2 h after HI. (E) Intranuclear neuronal staining (long arrow), labeling of nuclear membrane (bold
arrow) and strong immunoreactivity in some organelles, possibly mitochondria (short arrows) 24 h after HI. (F) Stronger staining in the endothelial cytoplasm (arrowheads)
24 h after HI. (G) Close-up view of immunoreactivity associated with the nuclear membrane (bold arrows), possibly at the site of a nuclear pore (thin arrow). (H) No
immunoreactivity was detected in negative control sections, without primary antibody, 24 h after HI. The arrow indicates a nucleolus.
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this activation was largely prevented by CX295 (Fig. 7). We con-
firmed that the Bcl-2 levels decreased upon thapsigargin treatment
and that this could be prevented by pretreatment with the calpaininhibitor. Also, release of caspase-12 from cellular membranes into
the cytosol was demonstrated in a calpain-dependent manner
(Fig. 7). There was no change in the levels of Bax in this paradigm,
neither by thapsigargin treatment, nor calpain inhibition (Fig. 7).
Fig. 6. Calpain inhibition prevented Bcl-2 reduction after HI. Bcl-2 in the cytosolic
fraction from cortical tissue, both from ipsilateral and contralateral hemispheres at
24 h after HI, was prevented from downregulation by calpain inhibition (CX295) in
the ipsilateral hemisphere after HI. The graph shows the relative amount of Bcl-2
remaining in the ipsilateral compared with the contralateral hemisphere. Actin was
used as a loading control (n = 8 for each group).
Fig. 7. Calpain inhibition prevented loss of Bcl-2 and decreased caspase-12
activation in IMR-32 cells after ionophore (thapsigargin) treatment. Expression of
the active 58 kDa m-calpain increased with ionophore stimulation and decreased
with concurrent calpain inhibition. The total level of Bcl-2 decreased with
increasing calpain activation and returned towards normal levels with increasing
calpain inhibition. The expression of caspase-12 in the cytosolic fraction increased
with calpain activation and decreased with calpain inhibition. The total levels of
Bax did not change after calpain activation.
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Previous studies have demonstrated that the major anti-apop-
totic Bcl-2 is expressed in the brain and that its expression levels
can regulate cell death following ischemic injury (Martinou et al.,
1994). It has been shown that Bcl-2 is localized on the outer
mitochondrial membrane, is highly expressed in the brain during
development and subsequently downregulated (Soane et al.,
2008). Bcl-2 acts by inhibiting pro-apoptotic Bcl-2 family member,
Bax, through heterodimerization (Sedlak et al., 1995). Bax is widely
expressed in the brain and Bax deficiency attenuated neonatal HI
brain injury (Gibson et al., 2001). Together, these and other studies
indicate that Bcl-2 family proteins play a crucial role in the regula-
tion of apoptotic signal transduction.
The expression of Bcl-2 and Bax after neonatal cerebral HI was
investigated by Ferrer and coworkers, using immunohistochemis-
try and immunoblotting of whole brain homogenates, but they
found only slight changes in Bcl-2 at 12 and 24 h after the injury
(Ferrer et al., 1997). This led them to conclude that these proteins
did not play a major role in determining the fate of the cells. In an
adult model of cerebral focal ischemia (Chen et al., 1995), Bcl-2
was found to be upregulated and located in the cytoplasmic
(non-nuclear) compartment 24 h after the insult, in cells suble-thally injured in non-infarcted areas or just outside the border of
the infarct. Within the infarct, they found only endothelial cells
showing Bcl-2 immunoreactivity. Control animals did not exhibit
any expression of Bcl-2. In this neonatal model, we detected posi-
tive cells also within the injured area after 24 h, in contrast to re-
sults from the adult ischemia model (Chen et al., 1995).
However, the intracellular location had changed from diffusely
cytoplasmic to nuclear. The increased expression of Bcl-2 in the in-
jured area may reflect an adaptive response of surviving neurons to
an ischemic insult. In accordance with the results from the adult
model, clearly positive endothelial cells could also be found exclu-
sively within the injured area.
Our findings, demonstrating a translocation of Bcl-2 to neuronal
nuclei in damaged areas after HI, support the notion that Bcl-2 is
involved in mechanisms other than those based on direct interac-
tion with Bax. The translocation was particularly apparent at 24 h
after HI, a time point at which the caspase-3 activity has reached
its maximum in this paradigm (Blomgren et al., 2001; Wang
et al., 2001). At this time point the bulk of Bcl-2 in injured areas ap-
peared to be concentrated to nuclei. The physiological impact of
the intracellular redistribution of Bcl-2 after neonatal cerebral HI
is unclear. One hypothesis is that it is involved in regulating nucle-
ar transport (Krajewski et al., 1993). An injured cell might respond
by sending a number of ‘‘SOS” signals to the nucleus. If it is possible
to rescue the cell, transcription factors (for example Hypoxia-
Inducible Factor, HIF) would need to reach their target genes to
activate genes coding for ‘‘first aid”-proteins and for this to occur,
functional nuclear pores must exist. Possibly, Bcl-2 could, through
its ability to interact with other proteins, act as a bait to attract and
escort them to the nuclear gate. Alternatively, Bcl-2 gating the nu-
clear pores might prevent traffic from cytosol to nucleus, an obser-
vation previously made in an over-expression study, where Bcl-2
prevented the nuclear translocation of the apoptosis-inducing
transcription factor p53 (Beham et al., 1997). We used subcellular
fractionation to elucidate the expression and possible translocation
of Bcl-2. We found that the levels of Bcl-2 in homogenates were de-
creased in the ipsilateral compared with contralateral hemispheres
at early recovery post-HI, but not at 24 h post-HI. In the mitochon-
drial fraction, the decrease was more pronounced, but delayed,
such that the difference between the ipsi- and contralateral hemi-
spheres was greatest at 24 h post-HI. The soluble, cytosolic fraction
contained a smaller amount of Bcl-2 than the particular fractions,
which facilitated quantification after immunoblotting. The nature
of the heavier band, migrating at an apparent molecular mass of
28 kDa, detected primarily in the soluble fraction, is not clear. It
might represent post-translational modification of Bcl-2, such as
phosphorylation (Hallin et al., 2006). Apparently, early after HI,
Bcl-2 is translocated from mitochondria to the cytosol and to
nuclei. Later during reperfusion, nuclear translocation of Bcl-2 con-
tinues, whereas cytosolic Bcl-2 is reduced. Nuclear translocation
was demonstrated using immunohistochemistry and immuno-
electron microscopy. We tried to demonstrate nuclear transloca-
tion also in nuclear fractions by using immunoblotting, but we
could not obtain pure nuclear fractions, free from mitochondrial
contamination (not shown). We did succeed in producing nuclear
fractions from adult brains without mitochondrial contamination,
but not from immature brains. We speculate that there is a pool
of mitochondria closely associated with the nuclei in the immature
brain, but this remains to be shown. For the same reasons, we have
been unable in other studies to produce immunoblots demonstrat-
ing nuclear translocation of AIF and therefore had to settle for
immunoblots showing decreased levels of AIF in mitochondrial
fractions, plus immunohistochemical evidence of nuclear translo-
cation (Zhu et al., 2003, 2007, 2005).
Calpains are cysteine proteases and have been demonstrated to
be involved in neuronal cell death together with caspase-3
C. Zhu et al. / Brain, Behavior, and Immunity 24 (2010) 822–830 829(Blomgren et al., 2001). One possible mechanism is calpain-medi-
ated, ischemia-induced cleavage of procaspase-12 or the loop of
Bcl-xL, demonstrating cross-talk between the calpain and caspase
families during neuronal cell death (Nakagawa and Yuan, 2000).
Calpain-induced cleavage of Bax has been shown earlier (Wood
and Newcomb, 2000; Wood et al., 1998), but there are very few
reports demonstrating calpain-dependent cleavage of Bcl-2
(Gil-Parrado et al., 2002). Our in vitro experiments revealed cal-
pain-dependent reduction of Bcl-2. The results may be interpreted
such that a massive influx of calcium, similar to the conditions in
the core of an ischemic infarct, promoting necrotic cell death, will
‘‘short-circuit” apoptotic mechanisms. This line of reasoning was
suggested earlier by Lankiewicz et al. reporting calpain-dependent
cleavage and inactivation of Apaf-1 (Lankiewicz et al., 2000). Con-
currently, calpain-dependent release of caspase-12 (Nakagawa and
Yuan, 2000) or partial cleavage and enhanced activation of cas-
pase-3 (Blomgren et al., 2001) may also contribute to the cross-talk
between excitotoxic and apoptotic mechanisms. Downregulation,
for example through proteolytic degradation, of the anti-apoptotic
Bcl-2 may be interpreted as an injurious mechanism, promoting
apoptotic cell death, provided that the cleavage products are inac-
tive or even pro-apoptotic. The physiological implication of this
finding was confirmed by in vivo administration of the calpain
inhibitor, CX295, which prevented downregulation of Bcl-2 after
HI. Earlier we have shown that CX295 treatment could, at least
partially, prevent activation of caspase-3 after HI (Blomgren
et al., 2001).
In summary, we demonstrate calpain-dependent reduction of
Bcl-2 as well as nuclear translocation of this protein after HI in
the immature brain. These changes might be of importance for
the life/death decision in the cell.Acknowledgments
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